ZhiChong Pharma Raises Tens of Millions RMB in A1 Round Led by Tianhui for AI Pet Drugs

ZhiChong Pharma (Suzhou) has closed a tens-of-millions-RMB A1 round led by Tianhui Capital, with Index Capital as exclusive financial adviser. Proceeds will advance core pipelines through the clinic, build an end-to-end AI drug R&D platform, and expand anti-infective, chronic-disease, CNS and anti-aging programs. Founded in 2023 as a Techbio, it runs ChemoFetch (small molecule) and OmniFetch (biologics) engines with 6+ FIC/BIC-potential pipelines; it says IND-to-NDA success in pet drugs could rise from roughly 10% for human small molecules to about 30–50%. More notes sit on our Investment channel.